Dear Editor,
We would like to share ideas on “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis.” [
1] In contrast to liver transplant recipients, patients with chronic liver disease exhibited a good humoral response to the coronavirus disease 2019 (COVID-19) vaccination, according to Cheung et al. [
1]. We also agree that COVID-19 is helpful in immunogenicity. The immunological response of a vaccine recipient with an underlying medical condition may be different from that of a healthy individual. Potential confounding factors must be taken into consideration while interpreting the current report. Prior asymptomatic COVID-19 infection is a possibility, and is not unusual [
2]. If there is no method to rule out prior cases of asymptomatic COVID-19, it would be challenging to evaluate the effectiveness of the vaccine.
FOOTNOTES
-
Authors’ contributions
RM: 50% ideas, writing, approval for submission; VW: 50% ideas, supervision, approval for submission
-
Conflicts of Interest
The authors declare no conflicts of interest.
Abbreviations
REFERENCES
- 1. Cheung KS, Mok CH, Mao X, Zhang R, Hung IF, Seto WK, et al. COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: a meta-analysis. Clin Mol Hepatol 2022;28:890-911.
- 2. Joob B, Wiwanitkit V. Letter to the editor: coronavirus disease 2019 (COVID-19), infectivity, and the incubation period. J Prev Med Public Health 2020;53:70.
Citations
Citations to this article as recorded by
- Correspondence on Letter regarding “COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis”
Ka Shing Cheung, Chiu Hang Mok, Wai Kay Seto, Man Fung Yuen
Clinical and Molecular Hepatology.2023; 29(1): 176. CrossRef
